HER3-DXd
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
Trial Timeline
Feb 26, 2024 → Oct 10, 2028
NCT ID
NCT06172478About HER3-DXd
HER3-DXd is a phase 2 stage product being developed by Daiichi Sankyo for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06172478. Target conditions include Advanced Solid Tumor, Melanoma, Head and Neck Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06099639 | Pre-clinical | Completed |
| NCT06172478 | Phase 2 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumor